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Abstract
Sepsis, characterized by a systemic inflammatory state that is usually related to Gram-negative bacterial infection, is a
leading cause of death worldwide. Although the annual incidence of sepsis is still rising, the exact cause of Gram-negative
bacteria-associated sepsis is not clear. Outer membrane vesicles (OMVs), constitutively secreted from Gram-negative
bacteria, are nano-sized spherical bilayered proteolipids. Using a mouse model, we showed that intraperitoneal injection of
OMVs derived from intestinal Escherichia coli induced lethality. Furthermore, OMVs induced host responses which resemble
a clinically relevant condition like sepsis that was characterized by piloerection, eye exudates, hypothermia, tachypnea,
leukopenia, disseminated intravascular coagulation, dysfunction of the lungs, hypotension, and systemic induction of tumor
necrosis factor-a and interleukin-6. Our study revealed a previously unidentified causative microbial signal in the
pathogenesis of sepsis, suggesting OMVs as a new therapeutic target to prevent and/or treat severe sepsis caused by Gram-
negative bacterial infection.
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Introduction
Sepsis is the principal cause of death in hospital populations, and
its incidence has increased over the past 20 years [1,2,3]. The
syndrome of sepsis develops when the host immune response to
infection becomes excessive, which results in systemic inflammation
and multiple organ failure. The inflammatory system becomes
hyperactive, which involves infiltration of inflammatory cells and
increased production of proinflammatory mediators such as tumor
necrosisfactor(TNF)-aandinterleukin(IL)-6[4,5,6].Moreover,the
coagulation system is triggered through extreme activation of pla-
telets, which provokes disseminated intravascular coagulopathy [3].
Gram-negative enteric bacilli such as Escherichia coli (E. coli),
which are components of the normal human colonic flora, provoke
sepsis through robust activation of the host immune system [7,8,9].
Microbial components such as lipopolysaccharide (LPS) or outer
membrane proteins derived from Gram-negative bacteria can
hyperactivate the host immune response via binding to pattern-
recognition receptors [10,11]. Although these soluble factors
secreted from bacteria are believed to play a central role in the
pathogenesis of sepsis, the exact cause of sepsis by Gram-negative
bacteria is not clear.
Membrane vesicles represent nanovesicles that are secreted
from cells as a mechanism for cell-free intercellular communica-
tion, which has been observed from archaea, Gram-negative
bacteria, and Gram-positive bacteria to eukaryotic cells
[12,13,14,15,16,17,18]. A wide variety of Gram-negative bacteria,
including E. coli, constitutively secrete outer membrane vesicles
(OMVs), which are defined as spherical, bilayered proteolipids
with an average diameter of 20–200 nm [12,13,14,15]. Previous
biochemical and proteomic studies have revealed that bacterial
OMVs are composed of outer membrane proteins, LPS, outer
membrane lipids, periplasmic proteins, DNA, RNA, and other
factors associated with virulence [14,19,20,21]. Growing evidence
suggests that OMVs released by Gram-negative bacteria play
diverse roles in polyspecies communities by enhancing bacterial
survival, killing competing bacteria, transferring genetic materials
and proteins between bacterial cells, delivering toxins into host
cells, and modulating the immune response in host environments.
Gram-negative bacteria involved in sepsis, such as E. coli,
Salmonella and Pseudomonas secrete OMVs [7,14,22]. OMVs are
enriched with LPS and outer membrane proteins known as potent
immunostimulators [15,23], and have been considered as vaccine
candidates for preventing infection by Gram-negative bacteria
[24,25]. Furthermore, previous study has revealed that meningo-
cocci release many OMVs in the plasma of patients suffering from
severe sepsis [26], but the physiological role of OMVs and their
possible contribution to sepsis have not been defined clearly. In
this study, we showed that OMVs derived from intestinal E. coli
are causative microbial signals in the pathogenesis of systemic
inflammatory response syndrome (SIRS) and sepsis-induced
lethality, through the systemic induction of TNF-a and IL-6.
PLoS ONE | www.plosone.org 1 June 2010 | Volume 5 | Issue 6 | e11334Results and Discussion
CLP (cecal ligation and puncture) is considered the most
appropriate model of sepsis because it mimics the features of
clinical peritonitis, including polymicrobial infection [27]. One
notable feature of the CLP model is the presence of E. coli in the
peritoneal fluid [28]. Initially, we confirmed that E. coli extracted
from the peritoneal fluid in C57BL/6 mice after CLP, identified as
E. coli through 16S rRNA sequencing, elaborated OMVs on their
surface (Fig. 1A). The OMVs purified from the supernate of
cultured E. coli were characterized by their spherical bilayered
shape (Fig. 1B). In analysis by dynamic light scattering, the
majority of the purified vesicles (75.0%) had a diameter of 25–
50 nm (Fig. 1C).
We next investigated whether OMVs derived from E. coli, which
is a commensal Gram-negative bacterium that lives in the gut,
caused death in mice. OMVs were lethal when injected
intraperitoneally into mice; 95% of the mice injected with 25
and 50 mg of OMVs died within 36 h after the injection (Fig. 2).
The lethality was not a consequence of bacterial contamination
because the OMV preparation was found to be sterile in vitro, and
the peritoneum and serum of mice injected with OMVs did not
contain any live bacteria (data not shown). These findings clearly
indicate that OMVs derived from Gram-negative bacteria were
lethal in mice.
To investigate whether the OMV-induced lethality in mice was
related causally to SIRS, sublethal doses of OMVs (1, 2, and 5 mg)
were injected intraperitoneally three times, as shown in Fig. 3A,t o
mimic the pathophysiological conditions under which OMVs are
secreted continuously. Although none of the doses induced
lethality, multiple injections of OMVs (5 mg) caused eye exudates
and piloerection (Fig. 3B). These symptoms were absent in groups
treated with 1 mg of OMVs and the group injected with 2 mg only
showed eye exudates (data not shown). Hence, we chose 5 mgo f
OMVs for the rest of the experiments.
We found a decrease in body temperature (hypothermia) after
multiple injections of 5 mg of OMVs (Fig. 3C). Moreover, we also
observed an increase in respiratory rate (tachypnea) (Fig. 3D) and
a decrease in the number of leukocytes in peripheral blood
(leukopenia) (Fig. 3E). Sepsis is considered positive if two or more
of the SIRS criteria are met (e.g., hypothermia, tachypnea, or
leucopenia [1]); therefore, our observation clearly indicates that
OMVs derived from intestinal E. coli induced host responses which
resemble a clinically relevant condition like sepsis.
Severe sepsis occurs when a condition induced by sepsis is
associated with dysfunction of organs distant from the site of
infection [29,30]. In our study, we found that the intraperitoneally
injected OMVs (5 mg) upregulated the number of infiltrated
leukocytes in bronchoalveolar lavage fluid (Fig. 4A) and increased
lung tissue permeability (Fig. 4B). Other notable features of severe
sepsis have been linked to disseminated intravascular coagulation
or hypotension [31,32,33]. Platelets in peripheral blood decreased
(Fig. 4C) and D-dimer levels in plasma increased (Fig. 4D) after
OMV treatment, which indicated that OMVs caused disseminat-
ed intravascular coagulation. Moreover, OMV injection caused a
drop in blood pressure from 103.266.7 to 65.4610.5 mmHg
(Fig. 4E), which is the major determinant of lethality [31,32].
Severe sepsis is accompanied by systemic inflammation that
results from excessive release of cytokines into the systemic
circulation [34,35]. Serum levels of TNF-a and IL-6 were
markedly enhanced 6 h after multiple injections of 5 mg OMVs
(Fig. 5A). Increased levels of such cytokines were observed
similarly in bronchoalveolar lavage fluid, which indicated the
presence of SIRS in lung tissues (Fig. 5B). On the other hand,
other SIRS-associated mediators, such as IL-1b, IL-10, and
interferon (IFN)-c in serum and bronchoalveolar lavage fluid
showed only a slight increase compared with TNF-a and IL-6
levels. TNF-a and IL-6 are well-known to be important cytokines
in the pathogenesis of sepsis, and the level of these cytokines in
serum is a crucial indicator of sepsis [4,5,6,36].
OMVs are enriched with LPS and outer membrane proteins
known as potent immunostimulators [14,15,19]. As reported,
OMVs derived from E. coli were enriched with LPS and many
proteins including outer membrane proteins (Fig. 6A); OMVs
Figure 1. Characterization of intestinal E. coli-derived OMVs. A.
Electron micrographs of thin sections of E. coli, showing the formation
of OMVs (arrows) on the cell surface. Scale bars, 100 nm (left) and
25 nm (right). B. Transmission electron microscopy image of purified
OMVs. Scale bar, 100 nm. C. Size distribution of OMVs according to
diameter as determined by dynamic light scattering.
doi:10.1371/journal.pone.0011334.g001
Figure 2. Induction of lethality in mice by intestinal E. coli-
derived OMVs. Mice were administered intraperitoneally once with
200 ml PBS that contained 0, 15, 25, or 50 mg OMVs derived from E. coli.
Survival was monitored every 12 h for 5 days (n=20; ***P,0.001,
compared to the PBS group).
doi:10.1371/journal.pone.0011334.g002
OMVs Induce SIRS
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investigated the role of vesicle-associated LPS on the development
of OMV-induced lethality. When OMVs (25 mg) or LPS (40 mg,
about twice the amount of LPS than that in 25 mg OMVs) were
injected intraperitoneally once into mice, LPS alone showed no
lethality in contrast to OMVs injection (Fig. 6B). We also
observed that co-treatment of polymyxin B with OMVs (25 mg)
resulted in a decrease in OMV-induced lethality. Furthermore, the
intraperitoneally injected OMVs (25 mg) caused delayed and
reduced lethality in CD14
2/2 mice than in wild-type mice
(Fig. 6C). CD14 is the co-receptor of LPS [37]. Although further
studies should be addressed, our findings support the conclusion
that OMVs act as more powerful SIRS inducers than LPS alone,
and that both vesicular LPS and other vesicular components
including proteins should be crucial in the pathogenesis of sepsis-
induced lethality.
The present study showed that intraperitoneal injection of
OMVs derived from intestinal E. coli induced host responses which
resemble a clinically relevant condition like SIRS that was
characterized by piloerection, eye exudates, hypothermia, tachy-
pnea, leukopenia, disseminated intravascular coagulation, dys-
function of the lungs, hypotension, systemic induction of TNF-a
and IL-6, and lethality. Earlier in vitro studies showed that OMVs
derived from Pseudomomas delivered multiple secreted virulence
factors into the cytoplasm of airway epithelial cells through a lipid
raft-mediated pathway [38]. Based on these observations,
Bomberger et al. proposed the possibility that direct delivery of
bacterial proteins by OMVs could occur without bacteria, even at
a far distance. We observed that intraperitoneal injection of
OMVs induced lung dysfunction through systemic inflammation.
Thus, OMVs might be efficient enough to induce systemic
inflammation in distant organs, although bacteria themselves are
important for the development of sepsis at the first infection site.
Understanding the microbial factors in the pathogenesis of
severe sepsis and sepsis-induced lethality is essential in developing
rational strategies for prevention and treatment of sepsis caused by
bacterial infection. Although LPS/endotoxin is considered the
critical microbial signal in Gram-negative bacterial sepsis [10],
increasing evidence suggests that outer membrane proteins are
also key components in sepsis induction. Lipoproteins, which are
the most abundant outer membrane proteins, can cause lethal
shock in mice [11], and when combined with LPS, they can cause
sepsis synergistically [39]. In addition, previous evidence indicates
that OMVs derived from Neisseria meningitidis are more potent
inducers of inflammation than purified LPS [23]. Note that OMVs
are especially enriched with outer membrane proteins, including
OmpA, OmpF, and NmpC, which are potent immunostimulators
[19]. It is interesting to note that Gram-negative bacteria involved
in sepsis, such as E. coli, Salmonella and Pseudomonas secrete OMVs
[7,14,22].
In conclusion, we demonstrated that the OMVs derived from
Gram-negative bacteria are previously unidentified causative
microbial signals in the pathogenesis of severe sepsis and sepsis-
induced lethality, through the induction of proinflammatory
cytokines, particularly TNF-a and IL-6. Although further studies
should be issued, our findings could lead to a better understanding
of the pathogenesis of sepsis and sepsis-related diseases caused by
Gram-negative bacterial infection, and could have major impli-
Figure 3. Induction of SIRS signs in mice by intestinal E. coli-derived OMVs. A. Study protocol for investigation of SIRS. Sublethal dose of
OMVs (5 mg) derived from E. coli was injected intraperitoneally three times at 12-h intervals, and the mice were checked for SIRS index. All
experiments in (B–E) were performed following this scheme using 5 mg OMVs derived from E. coli. B. Piloerection (left) and eye exudates (right). C
and D. Body temperature (C) and respiratory rate (D) examined after OMVs injection (n=5;**P,0.01 and ***P,0.001, compared to the PBS group).
E. Leukocyte number in blood collected from mice after OMV injection (n=5; ***P,0.001, compared to the 0 h group).
doi:10.1371/journal.pone.0011334.g003
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treatment of these syndromes.
Materials and Methods
Mice
We used 6–8 week old male wild-type mice and CD14
2/2 mice
of the C57BL/6 genetic background from the Jackson Laboratory.
Experimental protocols were approved by the Institutional Animal
Care and Use Committee at Pohang University of Science and
Technology, Pohang, Republic of Korea with approval number:
2009-01-0001.
Selection of intestinal E. coli after CLP
For CLP experiments, we anesthetized the mice, ligated the
cecum, punctured it once with an 18-gauge needle, and closed the
abdomen [40]. Forty hours after CLP, mice were anesthetized for
peritoneal lavage fluid collection. The fluid was cultured overnight
on Luria-Bertani agar plates at 37uC. A single colony was picked
and identified through 16S rRNA sequencing using primers 27f
and 1492r [41,42].
Preparation of OMVs from E. coli
Bacterial cultures grown in Luria-Bertani broth were pelleted
twice at 5,0006g for 15 min. The supernatant fraction was filtered
through a 0.45 mm vacuum filter and was concentrated by ultra-
filtration with a QuixStand Benchtop System (Amersham Biosci-
ences) having a 100-kDa hollow fiber membrane (Amersham
Biosciences). Another filtration through a 0.22 mmv a c u u mf i l t e r
was done to remove any remaining cells. OMVs were prepared by
pelleting after the centrifugation in a 45 Ti rotor (Beckman
Instruments) at 150,0006 g for 3 h at 4uC. OMVs diluted in
phosphate-buffered saline (PBS) were stored at 280uC [19]. The
protein concentration of OMVs was assessed by the Bradford assay
(Bio-Rad Laboratories). The size distribution of OMVs was mea-
sured by dynamic light scattering using Zetasizer Nano ZS (Malvern
Instruments) and was analyzed by Dynamic V6 software [43].
Transmission electron microscopy
After fixation with 2.5% glutaraldehyde, cultured bacteria were
pelleted and post-fixed in 1% osmium tetroxide for 1 h,
dehydrated in a graded series of ethanol, and embedded in epoxy
resin. Thin sections were prepared using diamond knives
(Diatome) on an MTX microtome (RMC Boeckeler Instruments),
placed on 150-mesh coated copper grids (EMS) and stained with
3% uranyl acetate and lead citrate. For analysis of OMVs, OMVs
in PBS were placed on 400-mesh copper grids and stained with
2% uranyl acetate. Images were obtained using a JEM1011
microscope (JEOL) at an accelerating voltage of 100 kV.
Periplasm and outer membrane preparations
Periplasm and outer membrane were purified as described
previously [44]. Briefly, spheroplasts were made from E. coli by
lysozyme (600 mg/g cells) and 0.1 M EDTA treatment. The
spheroplasts resuspended in ice-cold 10 mM Tris–HCl (pH 8.0)
were sonicated and centrifuged at 8,0006 g for 5 min. Whole
membranes were pelleted from the supernates at 40,0006g for 1 h
for outer membrane preparation. The preparation was pelleted at
40,0006 g for 90 min after incubation in 0.5% sarkosyl (Sigma
Chemical Co.) at 25uC for 20 min. Final pellets were resuspended
inice-cold10 mMTris–HCl(pH 8.0)andstoredat280uC.Protein
samples from whole-cell lysate, periplasm, outer membrane, and
OMVs wereanalyzed by sodiumdodecylsulfate-polyacrylamide gel
electrophoresis (10% resolving gel), followed by gel staining with
Coomassie brilliant blue R-250 (Sigma Chemical Co.).
Investigation of septic signs in mice
Rectal temperature and systolic blood pressure were measured
using a Digital thermometer (Natume) and a computerized tail-
cuff system (Visitech Systems), respectively. Respiratory rate was
measured in conscious, unrestrained mice using noninvasive
whole-body plethysmography (Allmedicus). For leukocyte count-
Figure 4. Induction of lung dysfunction, disseminated intra-
vascular coagulation and hypotension in mice by intestinal E.
coli-derived OMVs. A and B. Bronchoalveolar lavage fluid and lung
organs were prepared from mice injected with OMVs derived from E.
coli following Fig. 3A. The total number of leukocytes in bronchoalve-
olar lavage fluid (A) and wet-to-dry ratio of the lungs (B)( n=5;
*P,0.05, **P,0.01, and ***P,0.001, compared to the 0 h group).
C and D. Measurement of the number of platelets in peripheral blood
(C) and D-dimer levels in plasma (D) after OMV injection, as indicated in
Fig. 3A (n=5;**P,0.01 and ***P,0.001, compared to the 0 h group). E.
Systolic blood pressure examined after OMV injection (n=5; *P,0.05,
compared to the PBS group).
doi:10.1371/journal.pone.0011334.g004
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by cardiac puncture and put into EDTA-tube. Following 6 min
incubation with 1% HCl, the number of cells was counted using
the light microscopy.
Evaluation of inflammatory index in mice
Serum and bronchoalveolar lavage fluid were collected from
mice after treatment of OMVs. Each sample was centrifuged, and
the supernates were stored at 280uC until cytokines evaluation.
The pelleted cells in bronchoalveolar lavage fluid were resuspended
in PBS and counted using the light microscopy. For cytokines
measurements, the cytokines present in the serum and bronchoal-
veolar lavage fluid were analyzed by ELISA (R&D Systems).
Wet-to-dry ratio of the lungs
After the OMVs-treated mice were killed, lungs were taken
from the mice and weighed. They were weighed again after 2 days
of drying at 55uC, followed by calculation of wet-to-dry ratio [45].
Figure 5. Onset of systemic inflammation by intestinal E. coli-derived OMVs. Measurement of cytokines levels in serum (A) and
bronchoalveolar lavage fluid (B) by ELISA after OMV injection, as indicated in Fig. 3A (n=5;*P,0.05, **P,0.01, and ***P,0.001, compared to the
0 h group).
doi:10.1371/journal.pone.0011334.g005
Figure 6. Both vesicular LPS and other vesicular components are key factors in OMV-induced lethality. A. Coomassie-brilliant-blue-
staining of whole-cell lysates (WC), periplasmic proteins (PP), outer membrane proteins (OMP), and OMVs, each 10 mg. Molecular weight standards are
indicated on the left (kDa). Note that OMVs harbor 75 ng of LPS per 100 ng of OMV proteins. B. Survival curve of wild-type mice from a single
intraperitoneal injection of various samples as indicated (n=10; *P,0.05 and ***P,0.001, compared with PBS group). C. Survival curve of wild-type
and CD14
2/2 mice after single injection of 25 mg OMVs (n=10; *P,0.05 and ***P,0.001, compared to the PBS group).
doi:10.1371/journal.pone.0011334.g006
OMVs Induce SIRS
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Whole blood from heart was collected in EDTA-tube and
diluted 1:100 in 1% ammonium oxalate. Following the 10 min
incubation, the number of platelet was counted using the light
microscope. For D-dimer measurement, after treating the whole
blood with sodium citrate, D-dimer was quantified by Asser-
achrom D-dimer ELISA kit (Diagnostica Stago).
Statistical analyses
Survival curves were compared by the log-rank test. The rest of
the data were analyzed by Student’s t test using the GraphPad
Prism statistical program. P,0.05 was considered significant.
Results are expressed as means 6 SEM.
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